{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T06:16:23Z","timestamp":1776492983758,"version":"3.51.2"},"reference-count":0,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,10,9]],"date-time":"2008-10-09T00:00:00Z","timestamp":1223510400000},"content-version":"vor","delay-in-days":3144,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2000,3]]},"abstract":"<jats:p>We evaluated the efficacy and safety of the centrally acting cholinesterase inhibitor, rivastigmine tartrate, for patients with mild to moderately severe Alzheimer\u2019s disease (AD) with or without concurrent vascular risk factors (VRF). Patients (45\u201390\u2003years of age) were randomized to placebo (<jats:italic>n<\/jats:italic>\u2003=\u2003235), low\u2010dose rivastigmine (1\u20134\u2003mg\/day, <jats:italic>n<\/jats:italic>\u2003=\u2003233), or high\u2010dose rivastigmine (6\u201312\u2003mg\/day, <jats:italic>n<\/jats:italic>\u2003=\u2003231) for 26\u2003weeks. Efficacy measures included the Alzheimer\u2019s Disease Assessment Scale\u2010Cognitive subscale (ADAS\u2010Cog), the Clinician\u2019s Interview Based Impression of Change (CIBIC\u2010Plus), the Progressive Deterioration Scale (PDS), the Global Deterioration Scale (GDS), and the Mini\u2010Mental State Examination (MMSE). For efficacy and safety analysis, patients were categorized by baseline Modified Hachinski Ischemic Score (MHIS) for the determination of VRF (MHIS &gt;\u20030: presence of VRF; MHIS = 0: absence of VRF). As early as 12\u2003weeks, the mean change from the baseline ADAS\u2010Cog score was significantly different for those patients treated with high\u2010dose rivastigmine compared with placebo controls in both MHIS categories. However, the treatment difference between high\u2010dose rivastigmine and placebo at each time\u2010point was larger for patients with MHIS &gt;\u20030. The proportion of responders was significantly greater in the high\u2010dose rivastigmine group for each level of improvement. No differences were noted between treatment groups regarding safety evaluations. Rivastigmine is effective in both categories of patients, and those with VRF experience greater clinical benefit (cognition, activities of daily living, and disease severity).<\/jats:p>","DOI":"10.1046\/j.1468-1331.2000.00046.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T19:36:29Z","timestamp":1047411389000},"page":"159-169","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":118,"title":["An efficacy and safety analysis of Exelon<sup>\u00ae<\/sup> in Alzheimer\u2019s disease patients with concurrent vascular risk factors"],"prefix":"10.1111","volume":"7","author":[{"given":"V.","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Messina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Veach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,10,9]]},"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1468-1331.2000.00046.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1468-1331.2000.00046.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T07:51:55Z","timestamp":1698565915000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1468-1331.2000.00046.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,3]]}},"alternative-id":["10.1046\/j.1468-1331.2000.00046.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1468-1331.2000.00046.x","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,3]]},"assertion":[{"value":"2008-10-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}